A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
Jon Chung, Siraj Mahamed Ali, Jenni Davis et al. · Case Reports in Oncology · 2014
Suspected metastatic site lesions that are poorly differentiated present a diagnostic challenge when morphologic and immunohistochemical profiling cannot establish the primary tumor site. Here we present a patient diagnosed with both a malignant neoplasm in the lung and a right upper extremity (RUE) neoplasm of unclear histogenetic origin. Immunohistochemical staining performed on the latter specimen was inconclusive in determining the site of origin. Although the lung biopsy sample was insufficient for molecular testing, hybrid capture-based comprehensive genomic profiling (FoundationOne) identified an EML4-ALK rearrangement in the RUE lesion. Crizotinib treatment resulted in a major response in both the RUE and the lung lesions. This report illustrates the utility of comprehensive genomic profiling employed at the initial presentation of an unknown primary malignant neoplasm, which resulted in the front-line use of targeted therapy and a significant and sustained antitumor response.
Cited by 15 works. doi:10.1159/000367780 Open-access PDF
Authors
- Jon Chung
- Siraj Mahamed Ali
- Jenni Davis
- Karl Robstad
- Richard McNally
- Laurie M. Gay
- Rachel Erlich
- Norma Alonzo Palma
- Phil J. Stephens
- Vincent A. Miller
- Alfonso Cutugno
- Jeffrey S. Ross
References
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- ALK1 and p80 Expression and Chromosomal Rearrangements Involving 2p23 in Inflammatory Myofibroblastic Tumor
- Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
- Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers
- Tyrosine kinase gene rearrangements in epithelial malignancies
- Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer
- Identification of anaplastic lymphoma kinase fusions in renal cancer
- The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group
- ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
- Rearranged Anaplastic Lymphoma Kinase ( ALK ) Gene in Adult-Onset Papillary Thyroid Cancer Amongst Atomic Bomb Survivors